Literature DB >> 10024310

Angiotensin II type 1 receptor-mediated inhibition of K+ channel subunit kv2.2 in brain stem and hypothalamic neurons.

C H Gelband1, J D Warth, H S Mason, M Zhu, J M Moore, J L Kenyon, B Horowitz, C Sumners.   

Abstract

Angiotensin II (Ang II) has powerful modulatory actions on cardiovascular function that are mediated by specific receptors located on neurons within the hypothalamus and brain stem. Incubation of neuronal cocultures of rat hypothalamus and brain stem with Ang II elicits an Ang II type 1 (AT1) receptor-mediated inhibition of total outward K+ current that contributes to an increase in neuronal firing rate. However, the exact K+ conductance(s) that is inhibited by Ang II are not established. Pharmacological manipulation of total neuronal outward K+ current revealed a component of K+ current sensitive to quinine, tetraethylammonium, and 4-aminopyridine, with IC50 values of 21.7 micromol/L, 1.49 mmol/L, and 890 micromol/L, respectively, and insensitive to alpha-dendrotoxin (100 to 500 nmol/L), charybdotoxin (100 to 500 nmol/L), and mast cell degranulating peptide (1 micromol/L). Collectively, these data suggest the presence of Kv2.2 and Kv3.1b. Biophysical examination of the quinine-sensitive neuronal K+ current demonstrated a macroscopic conductance with similar biophysical properties to those of Kv2.2 and Kv3.1b. Ang II (100 nmol/L), in the presence of the AT2 receptor blocker PD123,319, elicited an inhibition of neuronal K+ current that was abolished by quinine (50 micromol/L). Reverse transcriptase-polymerase chain reaction analysis confirmed the presence of Kv2.2 and Kv3.1b mRNA in these neurons. However, Western blot analyses demonstrated that only Kv2.2 protein was present. Coexpression of Kv2.2 and the AT1 receptor in Xenopus oocytes demonstrated an Ang II-induced inhibition of Kv2.2 current. Therefore, these data suggest that inhibition of Kv2.2 contributes to the AT1 receptor-mediated reduction of neuronal K+ current and subsequently to the modulation of cardiovascular function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024310     DOI: 10.1161/01.res.84.3.352

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Multiscale model of dynamic neuromodulation integrating neuropeptide-induced signaling pathway activity with membrane electrophysiology.

Authors:  Hirenkumar K Makadia; Warren D Anderson; Dirk Fey; Thomas Sauter; James S Schwaber; Rajanikanth Vadigepalli
Journal:  Biophys J       Date:  2015-01-06       Impact factor: 4.033

2.  Molecular variability elicits a tunable switch with discrete neuromodulatory response phenotypes.

Authors:  Warren D Anderson; Hirenkumar K Makadia; Rajanikanth Vadigepalli
Journal:  J Comput Neurosci       Date:  2015-12-01       Impact factor: 1.621

Review 3.  Rostral Ventrolateral Medulla and Hypertension.

Authors:  Patrice G Guyenet; Ruth L Stornetta; Benjamin B Holloway; George M P R Souza; Stephen B G Abbott
Journal:  Hypertension       Date:  2018-09       Impact factor: 10.190

4.  Dual mechanisms of angiotensin-induced activation of mouse sympathetic neurones.

Authors:  X Ma; K Bielefeldt; Z Y Tan; C A Whiteis; V Snitsarev; F M Abboud; M W Chapleau
Journal:  J Physiol       Date:  2006-03-16       Impact factor: 5.182

5.  Inactivation of Native K Channels.

Authors:  Sodikdjon A Kodirov; Johannes Brachmann; Tatiana A Safonova; Vladimir L Zhuravlev
Journal:  J Membr Biol       Date:  2021-08-12       Impact factor: 1.843

Review 6.  GABA is a mediator of brain AT1 and AT2 receptor-mediated blood pressure responses.

Authors:  Alain G Dupont; Laura Légat
Journal:  Hypertens Res       Date:  2020-05-25       Impact factor: 3.872

7.  MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model.

Authors:  Xiaomeng Jia; Shaohua Zheng; Xinxing Xie; Yujiao Zhang; Weizong Wang; Zhongsu Wang; Yong Zhang; Jiangrong Wang; Mei Gao; Yinglong Hou
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.